PCRX Pacira Biosciences Inc.

Pacira BioSciences to Present at the 2020 Barclays Global Healthcare Conference

Pacira BioSciences to Present at the 2020 Barclays Global Healthcare Conference

PARSIPPANY, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: PCRX) today reported that it will present at the 2020 Barclays Global Healthcare Conference at 9:00 AM ET on Thursday, March 12, 2020. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at . A replay of the webcast will also be available for two weeks following the event.

About Pacira 

Pacira BioSciences, Inc. (NASDAQ: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, the company acquired the iovera⁰ system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit .

Company Contact:

Pacira BioSciences, Inc.

Christian Pedetti

(973) 254-4387

EN
09/03/2020

Underlying

PCRXPacira Biosciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacira Biosciences Inc.

 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Presents New Data on the Effects of Clinical Immuno...

Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee -- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 – -- An oral presentation of the data to be featured at the ASGCT Annual Meeting -- BRISBANE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to t...

May 15, 2025 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Hea...

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21st at 8:30AM ET.2025 Jefferies Global Healthcare Conference on Wednesday, June 4th at 8:45AM ET. ...

May 14, 2025 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Reports First Quarter 2025 Financial Results

Pacira BioSciences Reports First Quarter 2025 Financial Results -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the first quarter of 2025. First Quarter 2025 Financial Highlights Total revenues of $168.9 millionNet product sales of $136.5 million for EXPAREL, $23.3 million for ZILRETTA, and $5.1 million for iovera°Net income of $4.8 million, ...

May 8, 2025 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-...

Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis -- Data will be featured at EULAR Annual Congress – BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced new data from its ongoing Phase 1 study of its gene therapy candidate PCRX-201 (enekinragene inzadenovec). The is being presented at the 2025 European...

May 6, 2025 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences to Present New Data on Clinical Immunogenicity of I...

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis Data will be featured at the ASGCT 28th Annual Meeting BRISBANE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced an upcoming podium presentation of findings from its Phase 1 study of PCRX-201 (enekinragene inzadenovec), a locally administered gene therapy candid...

May 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch